The Facts and The Future Of Delta-8 Laws

This article is by Scott Mazza, Co-Founder and COO of Buffalo’s Vitality CBD.

It’s tough to think of a cannabinoid more controversial than delta-8 THC. This cannabis compound exists in a complex legal and scientific gray area, straddling the line between hemp-derived wellness product and illegal psychoactive substance. Such ambiguity has sparked intense debate among lawmakers, industry professionals, and consumers alike, making delta-8 laws a focal point in discussions about the future of cannabis regulation and the hemp industry.

As we approach this year’s revision of The Farm Bill, it’s crucial to clarify what we know, what we don’t, and what should happen next for this cannabinoid. With other synthesized cannabinoids also gaining prominence, there’s a pressing need for careful, science-based regulation that balances innovation with consumer safety. Only then can we unlock the potential of compounds like delta-8 while addressing legitimate concerns, ultimately shaping the broader cannabis landscape for years to come. Let’s explore the facts and the future of delta-8.

So, What Actually is Delta-8?

Chemically similar to its more famous cousin, delta-9 THC, delta-8 differs only by the location of a single double bond in its molecular structure. This slight variation results in milder psychoactive effects. Due to its scarcity in nature, delta-8 is typically synthesized from hemp-derived CBD through a process called isomerization. This method allows for large-scale production of delta-8 products, including oils, edibles, and vape cartridges.

Users report experiencing relaxation, pain relief, and mild euphoria without the intense anxiety or paranoia sometimes associated with delta-9 THC. However, the legal status of delta-8 remains complex. While the 2018 Farm Bill ushered in a new era and allowed for the proliferation of hemp products, state regulations vary widely. Currently, a dozen states have banned delta-8 outright, with some attempting to regulate it within legal marijuana markets and nearly two dozen lacking clear regulations altogether. This patchwork of laws has created a challenging landscape for both producers and consumers.

What We Know and What We Don’t About Delta-8

Early findings are promising. Current studies support the anecdotal view that the cannabinoid is like delta-9’s “nicer younger sibling,” offering similar benefits with fewer adverse reactions. A New York study found that delta-8 users predominantly experienced relaxation, pain relief, and euphoria. Notably, half of the participants reported using delta-8 to treat various health conditions, including anxiety, stress, depression, and chronic pain. On average, experiences of paranoia were minimal.

However, our knowledge gaps are still substantial. Research on delta-8 remains scarce compared to CBD, with most studies being anecdotal, not peer-reviewed, and lacking human subjects. The scientific community is still in the early stages of understanding delta-8’s full potential and risks.

Therefore, future research needs to employ nationally representative samples and more rigorous methods to better understand the cannabinoid’s prevalence and consequences. As we navigate this emerging field, balancing potential benefits with necessary precautions is crucial for the responsible development and use of delta-8 THC. This depends, however, on the legislative playing field following the end of this year.

What’s Next for Delta-8 Laws

This is a pivotal period for delta-8 and the wider hemp industry. Following a 12-month delay, lawmakers are set to update the five-year Farm Bill later this year. In May, however, a House committee approved an amendment to outlaw the sale of hemp-derived products containing “any quantifiable amount” of THC and ban synthetically produced cannabinoids.

This is a big deal that could change hemp as we know it. While I, like many in the industry, support the regulation of delta-8, it’s difficult to see the argument for complete prohibition. Banning historically doesn’t work and could devastate a $28 billion industry, financially cripple hemp farmers, and deprive consumers of products some rely on for pain relief.

At the same time, this argument is complicated by bad actors. As reported in Missouri Medicine, there are concerns surrounding delta-8’s chemical conversion processes, synthetic methods, and potential impurities. Some manufacturers use unsafe chemicals or unsanitary environments, potentially introducing harmful contaminants. 

Given these risks, regulators must strike a balance between protecting consumer safety and supporting industry innovation. Ideally, they should focus on production standards rather than outright prohibition. This approach is especially important as preliminary evidence suggests delta-8 may have a more favorable effect profile than delta-9, which is only becoming more available across the country as laws change and red tape lessens (as it should).

Let’s see what happens next. Hopefully, the government and industry can come to the table, weigh the risks and benefits, and put an end to poor production practices with delta-8 laws without hurting those businesses doing the right thing. By fostering collaboration between stakeholders, we can develop regulations that ensure product safety, maintain quality control, and allow responsible businesses to thrive. This considered approach will be key to shaping a sustainable future for delta-8 laws and the broader hemp industry. 

Watch this space. And, if necessary, call your representative.